Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Study limitation reported by the research below: “This is a post hoc exploratory analysis — results are hypothesis-generating, not confirmatory, despite the large phase III trial origin.”